Parvovirus B19 Infection Contributes to Severe Anemia in Young Children in Papua New Guinea
1Department of Infectious Diseases and Immunology, University of Sydney, Australia; 2Papua New Guinea Institute of Medical Research, Madang, and 3Papua New Guinea Institute of Medical Research, Goroka
Background.
Severe anemia (hemoglobin level, <50 g/L) is a major cause of death among young children, and it arises from multiple factors, including malaria and iron deficiency. We sought to determine whether infection with parvovirus B19 (B19), which causes the cessation of erythropoiesis for 3–7 days, might precipitate some cases of severe anemia.
Methods.
Archival blood samples collected in the Wosera District of Papua New Guinea, from 169 children 6 months–5 years old with severe anemia and from 169 control subjects matched for age, sex, and time were tested for B19 immunoglobulin M (IgM) by enzyme immunoassay and for B19 DNA by nested polymerase chain reaction (PCR). A total of 168 separate samples from children in the Wosera District were tested for B19 IgG.
Results.
A strong association between acute B19 infection (positive by both IgM and PCR) and severe anemia was found (adjusted odds ratio, 5.61 [95% confidence interval, 1.93–16.3]). The prevalence of parvovirus B19 IgG reached >90% in 6‐year‐olds.
Conclusions.
B19 infections play a significant role in the etiology of severe anemia in this area of malarial endemicity. Given the high levels of morbidity and mortality associated with severe anemia in such regions, the prevention of B19 infection with a vaccine might be a highly effective public health intervention.
Received 20 December 2005; accepted 16 February 2006; electronically published 14 June 2006.
-
(See the editorial commentary by Pasvol, on pages 141–2.)
Cited by
Online publication date: 15-Jul-2009.
Online publication date: 15-Feb-2008.
Online publication date: 1-Nov-2007.
CrossRef
Online publication date: 15-Jul-2006.
-
Potential conflicts of interest: none reported.
Financial support: Biotrin International, Ireland (parvovirus IgM and IgG test kits); PanBio Limited (Australia; assistance with shipping); University of Sydney, Faculty of Medicine Postgraduate Research Support Scheme; and Daphne Goulston Scholarship (travel assistance to J.W.).
-
J.W. and P.M. contributed equally to the study.





